Novo Nordisk shares jump 8% after Wegovy sales beat …
6 days ago · Novo Nordisk added that sales of Wegovy were 79% higher year-on-year in the third quarter, coming in at 17.3 billion Danish kroner. ... The news was taken as a signal that Novo Nordisk's efforts ...
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
5 days ago · COPENHAGEN, Nov 6 (Reuters) - Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring investors worried that...
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar …
5 days ago · Novo Nordisk (NYSE:NVO) is stealing the spotlight in the obesity drug market as Wegovy's sales skyrocketed by 76% year-over-year to DKK 38.3 billion, crushing analysts' forecasts. This explosive ...
Novo Nordisk CEO on Wegovy prices, supplies and compounding
5 days ago · LONDON, Nov 6 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%. "In ...
News Details - Novo Nordisk
Jul 25, 2024 · SELECT was a randomised, double-blind, parallel-group, placebo-controlled trial designed to evaluate the efficacy of Wegovy ® versus placebo as an adjunct to standard of care for prevention of MACE in people with established CVD with overweight or obesity with no prior history of diabetes.
News Details - Novo Nordisk
Mar 8, 2024 · Wegovy® approved in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease. Bagsværd, Denmark, 8 March 2024 – Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a label expansion for Wegovy ® based on a supplemental New Drug Application ...
News details - Novo Nordisk
PLAINSBORO, N.J., March 8, 2024 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Wegovy ® to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight along ...
News details - Novo Nordisk
Nov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with an initial BMI of 27 kg/m 2 or greater and established cardiovascular disease (CVD). A decision is ...
News Details - Novo Nordisk
Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The approval is based on the results from the STEP phase 3a clinical trial programme.
News details - Novo Nordisk
PLAINSBORO, N.J., June 4, 2021 /PRNewswire/ -- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the new drug application (NDA) for Wegovy ™ (semaglutide) injection 2.4 mg, the first-and-only prescription weight-loss …
- Some results have been removed